Impact of intestinal dysbiosis-related drugs on the efficacy of immune checkpoint inhibitors in clinical practice
| Autor: | R. Villatoro Roldan, Cristina Morales, M. Garrido-Siles, Francisco Rivas-Ruiz, F. Toscano, J. Jiménez-Castro, J. Valdivia, S. Estalella-Mendoza, M. J. Martínez-Bautista, Miguel-Ángel Berciano-Guerrero, L. de la Cruz-Merino, B. Pérez-Valderrama, Esteban Nogales-Fernández, Elisabeth Pérez-Ruiz, M. Rodriguez de la Borbolla Artacho, Antonio Rueda |
|---|---|
| Rok vydání: | 2020 |
| Předmět: |
Adult
Male 0301 basic medicine Drug Cancer Research medicine.medical_specialty Lung Neoplasms medicine.drug_class media_common.quotation_subject Antibiotics 03 medical and health sciences 0302 clinical medicine Adrenal Cortex Hormones Carcinoma Non-Small-Cell Lung Internal medicine medicine Humans Immune Checkpoint Inhibitors Melanoma Aged Retrospective Studies media_common Immune checkpoints inhibitors Aged 80 and over Proportional hazards model business.industry Hazard ratio General Medicine Middle Aged medicine.disease 030104 developmental biology Anti-Anxiety Agents Oncology 030220 oncology & carcinogenesis Concomitant Intestinal dysbiosis Clinical response Dysbiosis Biomarker (medicine) Female Antacids business Cohort study |
| Zdroj: | Digital.CSIC. Repositorio Institucional del CSIC instname |
| Popis: | [Purpose]: Intestinal dysbiosis has emerged as a biomarker of response to immune checkpoint inhibitors (ICIs). It can be caused by antibiotics, although it may also result from the use of other drugs that have been studied to a lesser extent. The objective of our study was to analyze the association between the use of potentially dysbiosis-related drugs and survival in patients treated with ICIs in the clinical practice. [Materials and methods]: A retrospective, multicenter, cohort study was conducted. Clinicopathological variables were collected and the concomitant use of drugs was analyzed. A descriptive analysis of variables and overall survival, estimated by the Kaplan–Meier method, was performed, and association with various independent variables was assessed using Cox regression. [Results]: We included 253 patients, mainly with non-small cell lung cancer and melanoma. The most commonly used drugs were acid reducers, prescribed to 55.3% of patients, followed by corticosteroids (37.9%), anxiolytic drugs (35.6%), and antibiotics (20.5%). The use of acid reducers (9 vs. 18 months, P [Conclusion]: Response to ICIs may be influenced by the use of drugs that lead to intestinal dysbiosis. Although a confirmatory prospective controlled study is required, our findings should be taken into account when analyzing ICI efficacy. |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|